SAM Holdings forms strategic review committee amidst continuing net loss

Returns from its proton beam therapy have been slower than expected.

The Singapore Institute of Advanced Medicine Holdings (SAM) has formed a strategic review committee (SRC) in its bid to address the company’s continuous net loss.

The ramp-up in SAM’s business on the proton beam therapy has been slower than expected due to delays in being included on the panels of healthcare providers of insurance companies, low patient flow, and competition.

The lower revenue with higher operating expenses has resulted in the group continuing to record net losses, negative working capital, and negative cash flow from operations.

The SRC, comprising of non-executive directors of the company, will assist the executive management team on various ongoing and new initiatives focused on improving proton beam therapy utilisation and photon radiation therapy facilities.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia